Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Park, Keunchil [1 ]
Lin, Chia-Chi [2 ]
Huang, Dennis Chin-Lun [3 ]
Shin, Heather Hye-Jung [4 ]
Bogenrieder, Thomas [5 ]
Tan, Daniel S. -W. [6 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[4] Boehringer Ingelheim Korea, Seoul, South Korea
[5] Boehringer Ingelheim Rcv, Vienna, Austria
[6] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Monoclonal antibody; IGF; Phase; 1; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-100
引用
收藏
页码：S554 / S555
页数：2
相关论文
共 50 条
  • [21] Afatinib in EGFR mutation positive advanced non-small cell lung cancer
    Davies, R. S.
    Brewster, A. E.
    Button, M. R.
    Lester, J. F.
    LUNG CANCER, 2016, 91 : S22 - S22
  • [22] A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer
    Riess, J.
    Schalper, K.
    Kelly, K.
    Shimoda, M.
    Luxardi, G.
    Merleev, A.
    Monjazeb, A.
    Danenberg, K.
    Maverakis, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S345 - S345
  • [23] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [24] Comorbidity in clinical trial patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Kosov, Maxim
    Kumar, Akhil
    Belotserkovskiy, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] IMPROVING TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4038 - 4038
  • [26] Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Rossi, Antonio
    Ciardiello, Fortunato
    Gridelli, Cesare
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 578 - 580
  • [27] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [28] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [29] Sequential versus standard chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase III randomised trial
    Paesmans, M.
    Berghmans, T.
    Lafitte, J. J.
    Lecomte, J.
    Alexopoulos, C. G.
    Van Cutsem, O.
    Giner, V.
    Efremidis, A.
    Scherpereel, A.
    Sculier, J. P.
    LUNG CANCER, 2006, 52 : S26 - S27
  • [30] A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Sculier, J.
    Lafitte, J.
    Lecomte, J.
    Alexopoulos, C.
    Van Cutsem, O.
    Giner, V.
    Efremidis, A.
    Scherpereel, A.
    Paesmans, M.
    Berghmans, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 367S - 367S
12345